Can-Fite BioPharma Ltd. (CANF)


NYSE MKT - NYSE MKT Real Time Price. Currency in USD
2.36-0.01 (-0.38%)
As of 2:09 PM EDT. Market open.
People also watch:
VBLTWGBSCNATAQXPBLRX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open2.35
Prev Close2.37
Bid2.38 x 600
Ask2.42 x 1100
Day's Range2.33 - 2.43
52wk Range1.52 - 7.85
1y Target EstN/A
Market Cap32.44M
P/E Ratio (ttm)-4.68
Beta1.40
Volume37,870
Avg Vol (3m)93,373
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire16 days ago

    Can-Fite's Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology

    The study titled, "Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial," was published in the August 2016 issue of the journal. The published study provides details regarding patient population, safety profile, and Piclidenoson's efficacy as compared to apremilast, a drug approved by the U.S. Food and Drug Administration to treat moderate to severe psoriasis and is marketed under the brand name Otezla® by Celgene.

  • PR Newswirelast month

    Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD

    NAFLD is characterized by excess fat accumulation in the form of triglycerides (steatosis) in the liver. According to a recent study published in Hepatology, an estimated 25% of the population in the U.S. has NAFLD, with a higher prevalence in people with type II diabetes. NAFLD includes a range of liver diseases, with NASH being the more advanced form, manifesting as hepatic injury and inflammation.

  • PR Newswire2 months ago

    OphthaliX Announces Phase II Glaucoma Data

    In this trial, no statistically significant differences were found between the CF101 treated group and the placebo group in the primary endpoint of lowering intra ocular pressure (IOP). High IOP is a characteristic of glaucoma.